Testimony before the FDA’s Cardiovascular and Renal Drugs Advisory Committee Regarding the Drug Cangrelor
February 12, 2014
View the Testimony as a PDF.
View the Presentation as a PDF.
View the Press Release.
Public Citizen strongly opposes approval of the anti-platelet drug cangrelor for use in patients undergoing coronary artery stenting procedures and for patients who need an IV anti-platelet drug while awaiting surgery. The clinical trials failed to show that cangrelor is effective for these uses, and the design of these trials was unethical because subjects assigned to the control group received substandard anti-platelet management.